Technical Analysis for CHRS - Coherus BioSciences, Inc.

Grade Last Price % Change Price Change
grade C 19.16 -3.55% -0.71
CHRS closed down 3.55 percent on Friday, January 17, 2020, on 78 percent of normal volume.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Up
Historical CHRS trend table...

Date Alert Name Type % Chg
Upper Bollinger Band Walk Strength 0.00%
Upper Bollinger Band Touch Strength 0.00%
Calm After Storm Range Contraction -3.55%
Narrow Range Bar Range Contraction -3.55%
NR7 Range Contraction -3.55%
Stochastic Reached Overbought Strength -3.55%
Upper Bollinger Band Walk Strength -3.55%
Multiple of Ten Bearish Other -3.55%
Inside Day Range Contraction -3.55%
Above Upper BB Strength -3.55%

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile

Coherus Biosciences, Inc., a late-stage clinical biologics platform company, focuses on developing and commercializing biosimilar products worldwide. Its clinical stage pipeline consists of CHS-0214, an etanercept biosimilar candidate, which is in two Phase III clinical trials for the treatment of rheumatoid arthritis and psoriasis; CHS-1420, an adalimumab biosimilar candidate that has completed a Phase I study to treat psoriasis or rheumatoid arthritis; and CHS-1701, a pegfilgrastim biosimilar candidate, which has completed a Phase I study for the treatment of breast cancer patients exhibiting chemotherapy-induced neutropenia. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus Biosciences, Inc. in April 2012. Coherus Biosciences, Inc. was founded in 2010 and is headquartered in Redwood City, California.
Medicine Biotechnology Biopharmaceutical Immunology Chemotherapy Breast Cancer Rheumatoid Arthritis Psoriasis Immunosuppressants Biosimilar Recombinant Proteins Treatment Of Breast Cancer Etanercept

Is CHRS a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 23.91
52 Week Low 10.83
Average Volume 1,049,574
200-Day Moving Average 18.67
50-Day Moving Average 18.40
20-Day Moving Average 18.38
10-Day Moving Average 18.58
Average True Range 1.00
ADX 15.35
+DI 23.57
-DI 17.70
Chandelier Exit (Long, 3 ATRs ) 17.58
Chandelier Exit (Short, 3 ATRs ) 19.80
Upper Bollinger Band 19.89
Lower Bollinger Band 16.86
Percent B (%b) 0.76
BandWidth 16.47
MACD Line 0.26
MACD Signal Line 0.07
MACD Histogram 0.1937
Fundamentals Value
Market Cap 983.79 Million
Num Shares 51.3 Million
EPS -2.60
Price-to-Earnings (P/E) Ratio -7.37
Price-to-Sales 3.37
Price-to-Book 17.33
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 20.63
Resistance 3 (R3) 20.73 20.35 20.39
Resistance 2 (R2) 20.35 19.97 20.30 20.30
Resistance 1 (R1) 19.75 19.74 19.56 19.65 20.22
Pivot Point 19.37 19.37 19.27 19.32 19.37
Support 1 (S1) 18.77 18.99 18.58 18.67 18.10
Support 2 (S2) 18.39 18.76 18.34 18.02
Support 3 (S3) 17.79 18.39 17.94
Support 4 (S4) 17.69